Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376703 | 0.85 | TP53 (0.79) | ALDH1A1TP53EPHX2HPGDNPC1 | |
| SCHEMBL12561700 | 0.85 | HPGD (0.72) | ALDH1A1TP53EPHX2HPGDGAA | |
| SCHEMBL2285784 | 0.83 | ALDH1A1 (0.76) | ALDH1A1TP53EPHX2NPC1GAA | |
| SCHEMBL12101129 | 0.82 | PKM (0.75) | ALDH1A1TP53EPHX2HPGDNPC1 | |
| SCHEMBL20240865 | 0.80 | ALDH1A1 (0.72) | ALDH1A1TP53EPHX2NPC1GAA | |
| SCHEMBL14365707 | 0.80 | MEN1 (0.69) | ALDH1A1EPHX2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8091601 | 0.79 | EPHX2 (0.88) | ALDH1A1EPHX2GAAMEN1KMT2A | |
| Zinc Ion SCHEMBL9443922 | 0.79 | NPC1 (0.63) | ALDH1A1TP53EPHX2NPC1GAA | |
| SCHEMBL3930409 | 0.79 | EPHX2 (0.66) | ALDH1A1TP53EPHX2HPGDNPC1 | |
| SCHEMBL14618817 | 0.78 | MEN1 (0.62) | ALDH1A1TP53EPHX2GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | ALDH1A1 3496/4885TP53 1450/4885EPHX2 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.